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Objectives: Gender disparities, particularly among young women with cardiovascular disease, are a growing cause for
concern. Depression is a prevalent and prognostically important comorbidity in peripheral arterial disease (PAD), but its
prevalence has not been described as a function of gender and age. Therefore, we compared depressive symptoms at the
time of PAD diagnosis and 6 months later by gender and age in PAD patients.
Methods: The study enrolled 444 newly diagnosed patients with PAD (32% women) from two Dutch vascular outpatient
clinics. Patients’ depressive symptoms were assessed with the 10-item Center for Epidemiological Studies Depression
Scale (CES-D) at baseline and 6 months later (CES-D scores >4 indicate significant depressive symptoms). Logistic
regression models were constructed to evaluate the relationship among four gender-age groups (women <65 and >65
years; men <65 and >65 years [reference category]) and baseline and 6-month follow-up depressive symptoms.
Results: Initially, 33% of women<65 years had significant depressive symptoms, and 6 months later, significant depressive
symptoms had developed in 19% of the other younger women. These rates were much higher than other gender-age
groups (range at baseline, 11%-16%; 6-month incidence, 6%-10%; P < .03). Adjusting for demographics and clinical
factors, women<65 years experienced a fourfold greater odds of baseline (odds ratio [OR], 4.3; 95% confidence interval
[CI], 2.2-8.7) and follow-up depressive symptoms (OR, 4.1; 95% CI, 2.0-8.4) compared with men >65 years, whereas
other gender-age groups were not at risk. Additional adjustment for change in the ankle-brachial index did not explain
the increased depression risk in younger women (OR, 3.5; 95% CI, 1.2-10.2).
Conclusions: Significant depressive symptoms are more common in younger women with PAD than in other gender-age
groups, both at the time of diagnosis and 6 months later. To eradicate gender-based disparities in PAD, depression
screening and monitoring in younger women may be an important direction for future research and intervention. (J Vasc
Surg 2010;52:637-44.)Morbidity and mortality rates in patients with periph-
eral arterial disease (PAD) range from 30% to 70% during
the 5 to 15 years after their diagnosis.1 PAD greatly affects
physical functioning, and PAD patients have greater func-
tional impairment and more rapid functional decline than
patients without PAD.2 Preliminary findings suggest that
women with PAD are at particularly high risk to experience
leg pain on exertion and rest, have poorer functioning, and
greater walking impairment than men with PAD.3
From the Center of Research on Psychology in Somatic diseases, Depart-
ment of Medical Psychology and Neuropsychology, Tilburg University,a
the Department of Vascular Surgery, St. Elisabeth Hospital,d and the
Department of Vascular Surgery, Twee Steden Hospital,e Tilburg; and
Mid America Heart Institute of Saint Luke’s Hospital,b and Department
of Internal Medicine, University of Missouri, Kansas City.c
This study was supported by the Netherlands Organization for Scientific
Research, The Hague, The Netherlands with a VICI grant (453-04-004)
to Dr Denollet.
Competition of interest: none.
Reprint requests: Kim G. Smolderen, PhD, Center of Research on Psychol-
ogy in Somatic diseases, Department of Medical Psychology, Tilburg
University, Warandelaan 2, 5037AB Tilburg, The Netherlands (e-mail:
k.g.e.smolderen@uvt.nl).
The editors and reviewers of this article have no relevant financial relationships
to disclose per the JVS policy that requires reviewers to decline review of any
manuscript for which they may have a competition of interest.
0741-5214/$36.00
Copyright © 2010 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2010.04.025Apart from the physical burden, depression is a com-
mon comorbidity in PAD patients, affecting approximately
one of five PAD patients.4-7 Depressive symptoms among
PAD patients are associated with substantially compro-
mised functional status6 and poor prognosis.8 Research in
patients with coronary artery disease, and in the general
population, suggest that younger women may be at partic-
ularly increased risk of experiencing significant depressive
symptoms than other gender-age groups.9 The degree to
which depressive symptoms differ as a function of gender
and age has not been examined in PAD, but is important to
establish because it maymediate the worse health status and
poorer outcomes of young women and may emerge as an
important potential target for intervention.
Given prior findings of depression in patients with
coronary artery disease, we hypothesized that relatively
younger women with PAD are especially at risk of expe-
riencing an increased risk of depressive symptoms com-
pared with other gender-age groups. The current study
examined baseline and 6-month follow-up rates of sig-
nificant depressive symptoms according to gender and
age groups in a prospective registry of PAD patients to
identify potentially actionable targets to improve the
outcomes of young women, a particularly vulnerable
group of PAD patients.
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This study was approved by the Institutional Review
Board at each participating hospital. All participants pro-
vided written informed consent.
Participants and study design. PAD patients present-
ing with symptomatic disease were consecutively enrolled
from two vascular outpatient clinics of the St. Elisabeth Hos-
pital (between September 2001 and June 2008) and the
TweeStedenHospital (March 2006 toMay 2008) in Tilburg,
TheNetherlands. Patients were included if they had an abnor-
mal resting ankle-brachial index (ABI) (0.90) or an abnor-
mal postexercise ABI (ABI decrease of 15% after exercise).10
The study excluded patients whohad ischemic rest pain, tissue
loss, ulcers, gangrene, significant cognitive impairment, severe
psychiatric comorbidities (eg, psychosis), insufficient knowl-
edge of the Dutch language, or life-threatening conditions.
All participating patients received a diagnostic workup,
including vascular laboratory assessment, and completed self-
report questionnaires at baseline and at 6 months of follow-
up. Information about clinical factors was obtained through
medical record abstraction at baseline. A subset of patients
(those enrolled afterMarch 2006) underwent repeated vascu-
lar laboratory assessment at 6 months of follow-up.
Assessment of depressive symptoms. Depressive
symptoms were evaluated with an abbreviated 10-item
version of the Center for Epidemiological Studies Depres-
sion Scale (CES-D).11,12 This measure has good reliability,
with a Cronbach  of .88. Using an optimal cutoff score of
4, the 10-item CES-D has a sensitivity of 97% and a
specificity of 84% for a diagnosis of major depression using
the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-IV) criteria13 in younger individuals,
and a sensitivity of 100% and specificity of 93% in adults
aged 60.11
Vascular laboratory assessment. A handheld Dopp-
ler ultrasonic instrument (Imexlab 9000; Imex Medical
Systems Inc, Golden, Colo) was used by trained technicians
to obtain systolic blood pressure readings in the right and
left brachial arteries, right and left dorsalis pedis arteries,
and right and left posterior tibial arteries. The ABI at rest
and after walking on a treadmill was registered according to
the current TransAtlantic Inter-Society Consensus guide-
lines.10 Walking distance until pain occurred (pain-free
walking distance) and maximum walking distance was reg-
istered in all patients.
Statistical analysis. Baseline characteristics were com-
pared among four gender-age groups—women 65 years
and 65 years and men 65 and 65 years—with the
latter serving as the referent group. Mean depressive symp-
tom scores and depressive symptom rates (CES-D 4) were
compared among these four gender-age groups using analysis
of variance for continuous variables and 2 tests for categoric
variables. Bonferroni correction was used in post hoc analyses
to control for type I errors. Three pairwise comparisons be-
tween men 65 years and the other gender-age categories
were performed. Assuming   .05 and three pairwise com-parisons, a value of P .02 was considered statistically signif-
icant in post hoc analyses.
To compare the relative strength of the association
between patient characteristics and baseline depressive
symptoms, we compared standardized measures of effect
using Cohen’s d (mean1 – mean2/pooled standard devia-
tion). This was calculated for those patient characteristics
that were considered to be clinically important, including
gender-age groups, partner status, education, working sta-
tus, hypercholesterolemia, hypertension, diabetes mellitus,
prior cardiac disease, prior cerebrovascular disease, chronic
renal failure, chronic lung disease, chronic back pain, hip or
knee osteoarthritis, smoking, body mass index, ABI, and
pain-free walking distance.
Multiple logistic regression models were then con-
structed to evaluate the unadjusted and adjusted relation-
ship among the four gender-age groups (men 65 years
were used as reference category) and baseline and 6-month
follow-up depressive symptoms. Baseline and 6-month
follow-up depressive symptoms were defined as CES-D
scores 4. Follow-up depressive symptoms consisted of
patients with persistent depressive symptoms (CES-D score
4 at baseline and follow-up) and incident depressive
symptoms (CES-D score 4 at baseline, but 4 at follow-
up).
Multivariable analyses were performed with adjust-
ment for disease severity (ABI), clinical factors (diabetes
mellitus, prior cardiac disease, prior cerebrovascular dis-
ease, chronic lung disease, chronic back pain), and so-
ciodemographic variables (marital status, education,
working status). Follow-up analyses were additionally ad-
justed for baseline depressive symptoms and whether pa-
tients received peripheral revascularization within the
6-month follow-up period.
Secondary analyses were performed in patients with
repeated vascular laboratory assessment. The changes in
ABI scores were calculated and added as a covariate in the
model to evaluate whether changes in disease severity con-
tributed to the association with depressive symptoms at the
6-month follow-up. All analyses were performed with SPSS
17.0 software (SPSS Inc, Chicago, Ill). Values of P  .05
were considered statistically significant.
RESULTS
At baseline, 634 eligible patients were screened for
depressive symptoms. At 6 months, 32 patients were not
able to provide follow-up data on depressive symptoms (17
died, 7 had a life-threatening condition, 4 were hospital-
ized, and 4 could not be contacted), and 132 did not return
the questionnaire, resulting in 470 patients (78.1%). Of
these, the CES-D questionnaires were incomplete for 26,
which precluded derivation of a score, leaving 444 patients
for our final analyses. Nonresponders did not systematically
differ from responders on baseline characteristics, including
age and gender, except that nonresponders were less likely
to have a partner (35% vs 26%, P  .01) and had a shorter
maximum walking distance (329 vs 378 meters, P  .04).
Importantly, mean baseline depressive symptoms were not
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responders (1.9 vs 2.0, P  .60).
Gender-age groups. The cohort consisted of 14%
women 65 years, 18% women 65 years, 34% men 65
years, and 34% men 65 years. There were significant
baseline differences among these gender-age groups in
marital status, education, working status, prior cardiac and
cerebrovascular disease, smoking status, ABI, use of aspirin,
calcium antagonists, -blockers, and nitrates (Table I).
Younger womenwith PADwere less likely to have prior
Table I. Baseline characteristics of the total sample and st
Variables
Women 65 years
(n  63)
Demographics
Age, mean (SD, range), y 56.4 (6.1, 37-64)b 72.
Socioeconomic, No. (%)
No partner 17 (27)
High school education 17 (27)
Working full- or part-time 31 (49)b
Medical history, No. (%)
Hypercholesterolemia 43 (68)
Hypertension 28 (44)b
Diabetes mellitus 11 (18)
Prior cardiac disease 11 (18)b
Prior cerebrovascular disease 6 (10)
Chronic renal failure 2 (3)
Chronic lung disease 9 (14)
Chronic back pain 8 (13)
Knee or hip osteoarthritis 6 (10)
Life-style factors
Smoked 30 days, No. (%) 45 (71)b
Body mass index, mean (SD) 26.9 (5.9) 2
Vascular laboratory assessment
Ankle-brachial index, mean (SD) 0.66 (0.15) 0
Walking distance
Pain-free, mean (SD), m 97.3 (121.1) 9
Maximum (SD), m 372.7 (307.2) 26
Revascularization, No. (%)
PTA 26 (41)
Bypass surgery 3 (5)
Endarterectomy 2 (3)
Medication use, No. (%)
Statins 45 (71)
Aspirin 30 (48)b
ACE inhibitors 12 (19)
Anticoagulants 7 (11)
Calcium antagonists 5 (8)b
-Blockers 13 (21)b
Diuretics 9 (14)
Nitrates 0 (0)b
Digoxin 0 (0)
Antiarrhythmics 0 (0)
Depression treatment, No. (%)
Antidepressants 6 (10)
Currently receiving counselingc 2 (4)
ACE, Angiotensin-converting enzyme; PTA, percutaneous transluminal an
aReference group for the other three gender-age categories.
bValues are statistically significantly different betweenmen 65 years and ge
gender-age categories were made using analysis of variance (Bonferroni cor
pairwise comparisons.
cAvailable in 253 patients.cardiac disease and to be treated with cardioprotectivemedication than men 65 years. Importantly, younger
women were more likely to be active smokers (71%).
Women 65 years were more likely to live without a
partner than men 65 years. Finally, younger men were
more likely to be more educated, to be actively working,
and to be smokers, but were less likely to have a history of
cardiac disease than men 65 years.
Significant depressive symptoms. Of the 444 pa-
tients screened for depressive symptoms, 75 (17%) had
significant baseline depressive symptoms (CES-D 4).
d by gender and age
Men 65 years
P value
years 65 yearsa
81) (n  150) (n  150)
, 65-92) 57.5 (5.0, 39-64)b 72.6 (5.0, 65-85) .0001
48)b 21 (14)b 36 (24) .0001
35) 23 (15)b 52 (35) .001
11)b 71 (47)b 5 (3) .0001
64) 95 (63) 95 (63) .91
59) 77 (51) 90 (60) .10
21) 30 (20) 39 (26) .47
38) 36 (24)b 75 (50) .0001
5)b 22 (15) 32 (21) .01
10) 9 (6) 14 (9) .31
14) 12 (8) 22 (15) .29
19) 16 (11) 22 (15) .40
19) 18 (12) 29 (19) .14
42) 93 (62)b 53 (35) .0001
5.5) 26.7 (5.0) 26.3 (4.9) .80
0.15) 0.67 (0.17) 0.63 (0.19) .01
106.6) 124.5 (131.8) 122.7 (151.9) .08
241.8) 444.6 (321.4) 370.0 (314.0) .001
28) 48 (32) 40 (27) .19
5) 7 (5) 4 (3) .77
0) 3 (2) 6 (4) .29
66.7) 88 (59) 105 (70) .14
64) 87 (58) 103 (69) .03
32) 49 (33) 57 (38) .06
19) 17 (11) 28 (19) .20
19) 35 (23) 37 (25) .04
44) 40 (27)b 72 (48) .0001
22) 26 (17) 30 (20) .61
6) 3 (2)b 12 (8) .02
3) 1 (1) 3 (2) .45
5) 2 (1) 8 (5) .08
4) 6 (4) 6 (4) .30
2) 4 (3) 1 (1) .35
sty; SD, standard deviation.
ge category. Three pairwise comparisons betweenmen 65 years and other
). A value of P  .02 was used as the level of statistical significance for theratifie
65
(n 
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rates at baseline were highest in women 65 years (33%),
followed by women 65 years and male PAD patients
(range, 11%-16%; P  .001). Importantly, at the 6-month
follow-up, significant depressive symptoms affected up to
40% of women 65 years, compared with 17% to 21% in
other gender-age groups (P .001). The incidence of new,
significant depressive symptoms at 6 months among pa-
tients who had not screened positive at baseline was 19% in
women 65 years, which was significantly higher com-
pared with the incidence of 6% to 10% in the other gender-
age groups (P  .03).
To facilitate the interpretation of these gender-age
associations, Cohen’s d effect sizes were calculated for the
association between gender-age groups and baseline de-
pressive symptoms, for relevant sociodemographic and
clinical factors, and disease severity indices (Fig 1). A much
larger effect size was observed for the association between
younger women and depressive symptoms compared with
the effect sizes for PAD severity indices. Other factors with
moderate effect sizes with baseline depressive symptoms
Table II. Mean depressive symptom scores and depressive
gender-age groups
Score variables
Women 65 years
(n  63)
Baseline
CES-D score, mean (SD) 2.7 (1.9)b
CES-D 4, No. (%) 21 (33.3)b
6-month follow-up
CES-D score, mean (SD) 2.7 (1.8)
CES-D 4, No. (%) 25 (39.7)b
Incident CES-D 4, No. (%) 12 (19.0)b
CES-D, Center for Epidemiological Studies Depression.
aReference group for the other 3 gender-age categories.
bValues are statistically significantly different betweenmen 65 years and ge
gender-age categories were made using analysis of variance (Bonferroni cor
pairwise comparisons.
Fig 1. Effect sizes of patient characteristics associated with base-
line depressive symptoms. ABI, Ankle-brachial index; PFWD,
pain-free walking distance.were having no partner and chronic lung disease.Risk estimates for gender-age groups and baseline
depressive symptoms. Risk estimates for the gender-age
groups and baseline depressive symptoms (CES-D 4) are
shown in Fig 2.Women65 years hadmore than threefold
greater odds for experiencing baseline depressive symptoms
(unadjusted odds ratio [OR], 3.2, 95% confidence interval
[CI] 1.5-6.8) compared with men 65 years (reference
group; Fig 2, A, left). Other gender-age groups were not
significantly associated with baseline depressive symptoms.
After adjusting for disease severity and clinical factors in
multivariable models, women 65 years remained at in-
creased risk of having significant depressive symptoms (ad-
justed OR, 4.3; 95% CI, 2.2-8.7; P  .0001; Fig 2, A,
right). Further adjustment for sociodemographic variables
did not change these results (adjusted OR for women65
years, 5.4; 95% CI, 2.6-11.4; P  .0001).
Risk estimates for gender-age groups and 6-month
depressive symptoms. At the 6-month follow-up, women
65 years had a threefold increased odds of depressive
symptoms (unadjusted OR, 3.1; 95% CI, 1.6-6.1; Fig 2, B,
left), but other gender-age groups were not significantly
associated with 6-month depressive symptoms. Adjusting
for PAD severity, clinical factors, revascularization, and
baseline depressive symptoms, women65 years remained
at increased risk of having significant depressive symptoms
(adjusted OR, 4.1; 95% CI, 2.0-8.4, P  .03; Fig 2, B,
right). Further adjustment for sociodemographic variables
(ie, marital status, education, working status) did not
change these results (adjusted OR for women 65 years,
2.9; 95% CI, 1.2-7.2; P  .0001).
Changes in PAD severity and depressive symptoms.
To evaluate whether changes in PAD severity explained the
association between gender-age and depressive symptoms
at 6 months of follow-up, change ABI scores were calcu-
lated. Repeated vascular laboratory assessment was avail-
able in 269 patients. Mean increase in ABI was 0.12 in
women65 years, 0.09 in women65 years, 0.10 in men
65 years, and 0.05 in men 65 years (P  .18). Risk
estimates of gender-age groups and depressive symptoms at
ptoms rates at baseline and at 6 months of follow-up by
years Mena 65 years 65 years
P value81) (n  150) (n  150)
(1.8) 1.8 (1.8) 1.8 (1.5) .01
(16.0) 24 (16.0) 17 (11.3) .001
(2.0) 1.9 (1.9) 2.0 (1.9) .02
(21.0) 26 (17.3) 26 (17.3) .001
(9.9) 9 (6.0) 14 (9.3) .03
ge category. Three pairwise comparisons betweenmen 65 years and other
). A value of P  .02 was used as the level of statistical significance for thesym
65
(n 
2.0
13
2.4
17
8
nder-a6 months of follow-up were evaluated, while adding
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observed for the association between increased ABI and a
lower risk of follow-up depressive symptoms (OR, 0.9; 95%
CI, 0.9-1.1; P  .13), but women 65 years remained at
increased risk of experiencing depressive symptoms at the
6-month follow-up (OR, 3.5; 95% CI, 1.2-10.2; P .02),
after adjusting for their greater improvements in ABIs.
DISCUSSION
In this prospective multicenter PAD registry, we found
that depressive symptoms were present in up to 33% of
women aged 65 years at the time of PAD diagnosis,
which was significantly more common than the 11% to 16%
rate in the other gender-age groups. Moreover, prevalence
rates significantly increased over time, affecting 40% of
younger women at 6 months of follow-up. Even after
adjustment for PAD severity, clinical factors, and sociode-
mographic variables, younger women experienced a more
than fourfold increased odds of significant depressive symp-
toms, both at baseline and at follow-up, than men 65
years. The other gender-age groups had no increased risk of
having significant depressive symptoms at baseline or at
follow-up. Importantly, the increased risk of depressive
symptoms in younger women may represent a large differ-
ence: point estimates for younger women were not over-
lapping with the estimates for the other gender-age groups,
Fig 2. Model estimates presented with odds ratios (OR
depressive symptoms defined as Center for Epidemiologi
follow-up depressive symptoms (CES-D4) for gender-a
index, diabetes mellitus, prior cardiac disease, prior cerebr
Follow-up analysis was additionally adjusted for baseline
follow-up.with the CIs showing little overlap.To our knowledge, this is the first study that highlights
the vulnerability of younger women with PAD in terms of
their mental health. Although depressive symptoms have
been demonstrated to be prevalent in approximately one of
five patients with PAD,6,7,14 they have never been specifi-
cally evaluated and found to be significantly high (40%)
among the subgroup of younger women with PAD. To put
these proportions in perspective, the average prevalence of
depression in age groups comparable to the PAD popula-
tion has been estimated to be 2% for a major depressive
disorder and 10% for minor depression in community-
dwelling people,15 with female/male depression ratios be-
ing similar to those that were found in our study. Signifi-
cant depressive symptoms have been reported to occur in
about 16% to 31% of patients that have recently experi-
enced an acute myocardial infarction16 and in approxi-
mately 30% in patients with diabetes.17
Recently, there has been an increased awareness for the
disproportionate high rates of depressive symptoms in
female—especially younger—cardiac patients, in whom,
similar to our study, prevalence rates up to 40% have been
reported9 and gender disparities in terms of adverse out-
comes18,19 and impaired health status.20,21 In contrast,
there is a paucity of research describing gender-specific
differences in PAD.
Although epidemiologic studies have demonstrated
d 95% confidence intervals (CI) of risk for (A) baseline
udies Depression (CES-D) score4, and (B) 6 months’
oups. *Multivariable analyses adjusted for ankle-brachial
ular disease, chronic lung disease, and chronic back pain.
essive symptoms and peripheral revascularization during) an
cal St
ge gr
ovasc
deprthat PAD is at least as common in women and men,22-24 a
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portion of women enrolled in clinical studies among pa-
tients with PAD and the awareness for gender-based differ-
ences in patients with PAD in daily clinical practice.25
Women with PAD are more likely to be undertreated,26
experience more physical disability,3 and have more adverse
outcomes after revascularization.27 Our current findings
support these prior reports of undertreatment, although
atherosclerotic risk factor control could have been more
optimal across all gender-age groups. Younger women,
especially, were less likely to receive cardioprotective med-
ication (eg, aspirin) than the other gender-age groups.
It is not clear why younger women are more susceptible
than the other gender age-groups to depressive symptoms.
Their cardiovascular profile or PAD severity did not explain
the higher rates of depressive symptoms in the current
study. In fact, PAD severity indices only accounted for a
small amount of the variation in baseline depressive symp-
toms, whereas the contribution of being a woman aged
65 years was associated with a much larger effect size.
Moreover, although the change in ABI severity over 6
months was larger in young women, they had more persis-
tent and new-onset depressive symptoms than other
gender-age groups. Other factors that were substantially
associated with depressive symptoms were having no part-
ner and chronic lung disease. However, adjusting for clin-
ical factors and sociodemographic factors such as educa-
tion, working, or marital status did not alter our findings.
Alternative explanations for higher rates of depressive
symptoms in younger women include the differential social
roles and demands they face, care responsibilities for their
families, combining work and home responsibilities, lower
income and job inequality, and being a single parent. All of
these may partially explain the increased susceptibility of
younger women to depressive symptoms and warrant fur-
ther investigation.28 Evidence for biologic mechanisms
(hormonal factors, gender differences in neurotransmitter
systems or genetic factors) that might explain these gender
differences is inconclusive and deserves further study.28
Finally, the tendency of women to report more depressive
symptoms than men29 could not explain our findings,
because prevalence rates of depressive symptoms in elderly
women were similar to men.
Although disease severity—as expressed by younger
women’s baseline ABI and 6-month changes in ABI—
could not explain their higher prevalence rates of depres-
sion, it is important to pay attention to the clinical profile of
younger women with PAD in the current study. The obser-
vation that smoking rates were high in this group is especially
worrisome, because smoking is one of the most powerful risk
factors for PAD progression, and the number of pack-years is
associated with disease severity, increased risk of amputation,
peripheral graft occlusion, and death.10,30 Therefore, smok-
ing cessation is considered a cornerstone of PAD riskmanage-
ment.
From a clinical perspective, smoking cessation will be
an enormous challenge in those presenting with depressive
symptoms because the two are often intertwined, andsmoking may be considered as a way of self-medicating
patients’ levels of distress.31 Taking away this “medication”
in depressed patients will require intense follow-up, addi-
tional supportive strategies, and referral for counseling
should be considered to prevent further exacerbation of
depressive symptoms.31 Our results suggest that younger
women may particularly benefit from such additional sup-
portive measures.
Finally, despite the disproportionate distribution of
depressive symptoms across gender-age groups, it is nota-
ble that receiving antidepressants or counseling for depres-
sive symptoms did not significantly differ as a function of
gender-age in the current study, suggesting undertreat-
ment of depressive symptoms in younger women. The low
proportion of depression treatment in patients with signif-
icant depressive symptoms highlights a potential opportu-
nity to improve their treatment, particularly given that
previous reports have demonstrated that depressive symp-
toms are associated with greater physical disability in men
and women with PAD6,7 and with poor prognosis in men
with PAD.8
Apart from the implications for prognosis, depressive
symptoms deserve to be treated in their own right to reduce
the burden of depression itself. Increasing awareness by
clinicians for the increased depressive symptom burden and
the potential challenges associated with untreated depres-
sive symptoms among patients with PAD in general, and
particularly in younger women with PAD, will be an impor-
tant first step. The preparedness to incorporate quality-of-
care improvements in routine clinical care for PAD patients
that target these symptoms may be crucial action steps in
this regard.
Collaborative care models—led by a depression care
manager—that focus on improving case finding, referral,
patient education, and activation have been previously suc-
cessfully implemented in other patient groups32,33 and
have been able to improve depression recognition and
quality of life.34,35 These quality-of-care improvements
aimed at improving depression detection and outcomes
among patients with a chronic disease may also be necessary
to optimize risk management in patients with PAD.
Our study results should be interpreted in the context
of the following potential limitations: no systematic depres-
sion screening protocol using a psychiatric interview was
implemented; therefore, no diagnosis of major depression
according to DSM-IV criteria could be established. On the
other hand, the brief self-report instrument that was used
can be easily implemented in clinical practice and has been
shown to have high concordance with the diagnosis of
major depression.11
Furthermore, our findings may not be generalizable to
community-dwelling individuals with PAD or to PAD pa-
tients seen in primary care, because our patients repre-
sented only those that consulted a vascular surgeon for
symptomatic PAD. As such, we may have underestimated
the magnitude of the problem, because PAD is often
under-recognized in women, possibly due to the atypical
presentation of PAD symptoms.25
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(33% to 49%), the present study results may also not be
generalizable to clinics that have lower invasive treatment
rates among this population.
Finally, although we were able to adjust for clinically
important confounders in our analyses, the possibility of
residual confounding remains. More specifically, a larger
sample size for each of the gender-age groups, and espe-
cially among female subgroups, would have enabled us to
more reliably adjust for all potential confounders of depres-
sion. Future mediation studies in larger samples will thus be
needed to give more insight in mechanisms that explain
these increased prevalence rates. Clinicians, however, do
not have the capacity to adjust for multiple risk factors in
daily clinical practice, and as such, crude prevalence rates
seem to provide important insights as well. Therefore, the
current findings should not stop clinicians involved in care
for patients with PAD from being aware of the increased
prevalence of depressive symptoms among relatively
younger women with PAD, and especially the challenging
copresentation of depressive symptoms with increased
smoking rates.
CONCLUSIONS
The present study suggests that younger women with
PAD are more prone to significant depressive symptoms
than are other gender-age groups: up to 33% experienced
depressive symptoms at baseline, and this increased to 40%
at follow-up. Future research will need to further develop
this body of research, examining explanations for these
gender-age related differences. Meanwhile, opportunities
to improve detection and treatment facilities for depressed
PAD patients need to be explored, because these strategies
will be necessary to further optimize PAD management in
all patients, but especially in younger women with PAD.
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